Amicus Therapeutics News

Amicus Therapeutics Analyst Ratings

BenzingaMay 30 10:53 ET

Amicus Therapeutics Analyst Ratings

BenzingaMay 14 07:56 ET

Amicus Therapeutics Analyst Ratings

BenzingaMay 10 05:43 ET

Amicus Therapeutics Analyst Ratings

BenzingaMar 18 07:48 ET

Amicus Therapeutics Analyst Ratings

BenzingaFeb 29 13:46 ET

Morgan Stanley Upgrades Amicus Therapeutics to Overweight, Raises Price Target to $20

BenzingaDec 19, 2023 09:09 ET

Amicus Therapeutics Analyst Ratings

BenzingaDec 19, 2023 09:07 ET

Amicus Therapeutics: Strong Sales Performance and Future Profitability Hold Promise – A Buy Recommendation

TipRanksNov 10, 2023 06:27 ET

Amicus Therapeutics Receives Buy Rating Amid Strong Q3 and Optimistic Full-Year Revenue Forecast

TipRanksNov 9, 2023 08:55 ET

Amicus Therapeutics Analyst Ratings

BenzingaNov 9, 2023 08:54 ET

Morgan Stanley Maintains Equal-Weight on Amicus Therapeutics, Lowers Price Target to $14

BenzingaOct 10, 2023 11:17 ET

Amicus Therapeutics Analyst Ratings

BenzingaOct 10, 2023 11:17 ET

UBS Ups Price Target on Amicus Therapeutics to $20 From $19, Maintains Buy Rating

MT NewswiresSep 29, 2023 10:42 ET

Amicus Therapeutics Analyst Ratings

BenzingaSep 29, 2023 07:24 ET

UBS Adjusts Amicus Therapeutics Price Target to $19 From $17, Maintains Buy Rating

MT NewswiresAug 9, 2023 09:54 ET

Morgan Stanley Reiterates Equal-Weight on Amicus Therapeutics, Maintains $15 Price Target

BenzingaJul 11, 2023 08:57 ET

BofA Securities Adjusts Price Target on Amicus Therapeutics to $17 From $16, Maintains Buy Rating

MT NewswiresMar 28, 2023 11:24 ET

The Latest Analyst Ratings for Amicus Therapeutics

BenzingaMar 28, 2023 11:04 ET

B of A Securities Maintains Buy on Amicus Therapeutics, Raises Price Target to $17

BenzingaMar 28, 2023 10:24 ET

Goldman Sachs Adjusts Amicus Therapeutics' Price Target to $11 From $10, Keeps Neutral Rating

MT NewswiresMar 2, 2023 12:30 ET